, , and Mutations Correlated with Different Clinicopathological Features: an Analysis of 691 Melanoma Patients from a Single Center
Overview
Authors
Affiliations
Background: Discrepancies in genetic alterations found in melanoma are conspicuous between different ethnic groups. With the approval of BRAF- and MEK-targeted inhibitors in China, it is necessary to further elucidate the landscape of gene mutation in Chinese melanoma patients.
Methods: The frequency and distribution of , , and mutations in 691 melanoma patients was determined, and the statistical significance of correlations between different gene mutations and clinicopathological features was analyzed.
Results: Among a total of 691 patients, mutation was found in 166 patients (24.0%), and V600E was the prominent genetic alteration (145/166, 87.3%). Statistical analyses showed that younger patients (<60) had a higher mutation rate than older patients (≥60, P=0.000), and the frequency of mutation was more likely to be lower in patients with the following: melanoma located in an extremity (P=0.000), acral-lentiginous melanoma subtype (P=0.000), thinner melanoma thickness (P=0.047), and no ulceration (P=0.030). The frequency of mutation was 12.6% (38/302), and primarily involved codon 61 in exon 3 and codon 12 in exon 2. Mutation of was detected in 65 patients (9.4%), and the most common site of mutations was L576 in exon 11 (29/65, 44.6%). Patients with or mutation had higher Clark level (P=0.035 and 0.047, respectively) and were more likely to have melanoma located in an extremity (P=0.003 and 0.009, respectively) than those without such mutation. The concordance of gene mutations between paired primary and metastatic lesions was 89.6% (60/67), and visceral metastases showed the highest distribution of gene mutations versus primary melanomas (100.0%) compared with lymph nodes (90.9%) and cutaneous metastases (83.3%).
Conclusions: In this large cohort of Chinese melanoma patients, the frequencies of and mutations were lower than those observed in Caucasian cohorts, but the clinicopathological features of , , and mutation were consistent. Paired primary and metastatic lesions showed high concordance of gene mutations.
Olajossy B, Wronski N, Madej E, Komperda J, Szczygiel M, Wolnicka-Glubisz A Biomolecules. 2025; 14(12.
PMID: 39766280 PMC: 11674099. DOI: 10.3390/biom14121573.
Munoz-Barrera A, Rubio-Rodriguez L, Diaz-de Usera A, Jaspez D, Lorenzo-Salazar J, Gonzalez-Montelongo R Life (Basel). 2022; 12(11).
PMID: 36431075 PMC: 9695713. DOI: 10.3390/life12111939.
Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH.
Hung K, Luebeck J, Dehkordi S, Colon C, Li R, Wong I Nat Genet. 2022; 54(11):1746-1754.
PMID: 36253572 PMC: 9649439. DOI: 10.1038/s41588-022-01190-0.
Yang L, Liu Y, Wang T Front Med (Lausanne). 2022; 9:847382.
PMID: 35692550 PMC: 9174787. DOI: 10.3389/fmed.2022.847382.